TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27469583
Drug: Cyclophosphamide (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (2.0 mg/kg per day for 12 months followed by placebo for 12 months)
Study: 20496538
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medroxyprogesterone 500 mg/d, megestrol acetate 320 mg/d, oral supplementation with eicosapentaenoic acid (EPA), L‐carnitine 4 g/d, thalidomide 200 mg/d
Study: 20496538
Drug: Medroxyprogesterone 500
Normalized name: medroxyprogesterone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone 500 mg/d or megestrol acetate 320 mg/d
Study: 8862721
Drug: Methylprednisolone 40
Normalized name: methylprednisolone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 40 mg
Study: 2885298
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of propranolol
Study: 1696669
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of brefanolol
Study: 1696669
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of brefanolol
Study: 17419685
Drug: CEE (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (conjugated equine oestrogen) 0.6 mg/day
Study: 17419685
Drug: MPA (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (medroxyprogesterone acetate) 10 mg/day
Study: 17419685
Drug: CEE (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (conjugated equine oestrogen) 0.6 mg/day and MPA (medroxyprogesterone acetate) 10 mg/day
Study: 15308069
Drug: 0.25 U.kg(‐1).d(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 U.kg(‐1).d(‐1) of rhGH treatment on 7‐10 PBD, n=16
Study: 11217907
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (1000 microg day(‐1))
Study: 1434911
Drug: Ondansetron, 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron, 16 mg three times daily for 4 weeks
Study: 2997829
Drug: Carbamazepine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (average dosage 860 mg/day, average duration 29 days)
Study: 26687471
Drug: L-PRF- group
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF- group (n = 18)
Study: 20554983
Drug: Protease‐inhibitor group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease‐inhibitor group
Study: 16553019
Drug: Tiagabine 4
Normalized name: tiaGABine 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 4 mg
Study: 16553019
Drug: Tiagabine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 8 mg
Study: 23526959
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment
Study: 10664331
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation with oral antibiotics (kanamycin and metronidazole three times on the day before surgery)
Study: 10664331
Drug: Mechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical preparation alone (group 1)
Study: 17373639
Drug: Three daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three daily injections of lispro plus NPH
Study: 15800765
Drug: (18)F FDG
Normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (18)F FDG PET after neoadjuvant treatment
Study: 2775617
Drug: L-648,051 12.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-648,051 12.0 mg
Study: 778880
Drug: L-dopa with
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa with carbidopa
Study: 778880
Drug: Anticholinergic drugs
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drugs and/or amantadine
Study: 10333382
Drug: Clonidine with
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine with antagonist
Study: 2007319
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg caffeine, t.i.d., administered orally during one of the 8-day periods
Study: 17692448
Drug: Amisulpride (458.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (458.3 mg/day)
Study: 7625194
Drug: Moclobemide (378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (378 mg +/‐ 76 mg/day)
Study: 7625194
Drug: Fluoxetine (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (36 mg +/‐ 8 mg/day)
Study: 26939318
Drug: Fire-needle treatment
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire-needle treatment (once every two days for 30 days, 15 times total)
Study: 19747247
Drug: Methylaminolevulinate (MAL)
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylaminolevulinate (MAL) 160 mg/g cream
Study: 16675905
Drug: Temocapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril (1 mg daily)
Study: 21923715
Drug: Mesalazine tablets
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine tablets (3 g/day)
Study: 15606398
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (micropellets and tablets)
Study: 11748520
Drug: Nitroglycerin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (2 microg/kg/min infusion)
Study: 11748520
Drug: Milrinone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50 microg/kg loading dose)
Study: 8491393
Drug: Loperamide‐N‐oxide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide‐N‐oxide (3 mg orally twice daily)
Study: 3046883
Drug: Cicletanine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 12.5 mg daily
Study: 3046883
Drug: Cicletanine 25
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 25 mg daily
Study: 3046883
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg daily
Study: 3046883
Drug: Cicletanine 100
Normalized name: cicletanine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 100 mg daily
Study: 3046883
Drug: Cicletanine 200
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 200 mg daily
Study: 3046883
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg daily (12 weeks)
Study: 18450322
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus conventional-dose epirubicin (GE)
Study: 11833826
Drug: Lovastatin ER
Normalized name: lovastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin ER 40 mg
Study: 2672652
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg isosorbide dinitrate s.r. (slow release)
Study: 25205361
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPD) at a dosage of 0.5 to 0.8 mg/kg/d
Study: 20837928
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/d for 3 days before surgery
Study: 22192670
Drug: Atorvastatin (ex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (ex vivo)
Study: 11599659
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 IU s.c. once weekly (q.w.)
Study: 10612483
Drug: Cetrorelix (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (10 mg daily subcutaneous injections for five days and 60 mg depot)
Study: 10612483
Drug: Cetrorelix (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (10 mg daily intramuscular injections for five days and placebo depot)
Study: 10612483
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily and depot injections)
Study: 7756472
Drug: Dapsone/pyrimethamine (200/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone/pyrimethamine (200/75 mg once weekly)
Study: 7742423
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (300 mg once every 4 weeks)
Study: 31634023
Drug: Wixela Inhub
Normalized name: Wixela Inhub
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Wixela Inhub (FP/salmeterol 100/50 μg)
Study: 31634023
Drug: Advair Diskus
Normalized name: Advair Diskus
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Advair Diskus (FP/salmeterol 100/50 μg)
Study: 28267249
Drug: ASA 325
Normalized name: ASA 325 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 325 mg once-daily (pooled data)
Study: 20880870
Drug: Cylinder oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylinder oxygen provided at 6 l/min intranasally during activities provoking breathlessness
Study: 16796502
Drug: Videoconference telepsychiatry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconference telepsychiatry (VCTP) treatment
Study: 16796502
Drug: Face-to-face conventional
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face conventional (F2FC) treatment
Study: 16796502
Drug: Both VCTP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both VCTP and F2FC treatments
Study: 12752071
Drug: Antifibrinolytic agents
Normalized name: ANTIFIBRINOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrinolytic agents (tranexamic acid)
Study: 12752071
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory agents (mefenamic acid)
Study: 9209517
Drug: Preoperative intraluminal
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intraluminal brachytherapy (IBT) - moderate-dose group (16-40 Gy; n = 96)
Study: 9209517
Drug: Preoperative intraluminal
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intraluminal brachytherapy (IBT) - high-dose group (40-80 Gy; n = 19)
Study: 3312501
Drug: Dilevalol 200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 200-800 mg/day
Study: 24618385
Drug: ATG-F 9
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-F 9 mg/kg
Study: 22409587
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) for bifurcation lesions
Study: 321727
Drug: Droperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (10 mg)
Study: 6703348
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 2 mg
Study: 8143451
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg
Study: 15672012
Drug: Mifepristone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 400 mg
Study: 2782650
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection (250 sec) of 10 mg hypobaric tetracaine with epinephrine
Study: 2782650
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection (10 sec) of 10 mg hypobaric tetracaine with epinephrine
Study: 2569394
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of somatostatin in 2 ml saline (Group I)
Study: 2569394
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of somatostatin in 10 ml saline (Group II)
Study: 776314
Drug: Thioridazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (25 mg)
Study: 14610048
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg every 28 days for 2 years)
Study: 9797818
Drug: Granisetron via
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron via drip infusion with 100 ml of normal saline 30 minutes prior to CDDP administration (Group A)
Study: 9797818
Drug: Direct injection
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct injection of granisetron into the CDDP containing bottle (Group B)
Study: 338009
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate inhalation (800 microgram daily)
Study: 28249970
Drug: Ibandronate (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (local bisphosphonate treatment)
Study: 23952889
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg of NAC
Study: 23952889
Drug: 2,400 mg
Normalized name: pancreatin/lipase/protease/amy 2,400 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,400 mg of NAC
Study: 21412846
Drug: Clozapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (300 mg/day)
Study: 21412846
Drug: Haloperidol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (15 mg/day)
Study: 19365587
Drug: Clopidogrel 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 450 mg loading and 75 mg/d thereafter added to standard reperfusion therapy (group 2, n: 85)
Study: 17460488
Drug: Lactobacillus LB
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus LB (Lacteol) plus oral rehydration salts (ORS)
Study: 17460488
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral rehydration salts (ORS)
Study: 9133767
Drug: Venlafaxine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine and therapy
Study: 9133767
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and therapy
Study: 8432296
Drug: Alteplase (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (10 mg bolus injection + 5000 IU heparin bolus injection, followed by 90 mg alteplase over 3 h)
Study: 8432296
Drug: Anistreplase (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase (30 mg iv over 5 min)
Study: 17868006
Drug: Zonisamide (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (50-100 mg/day)
Study: 12135034
Drug: 68 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68 g polyethylene glycol (PEG) laxative
Study: 10426889
Drug: Proprietary base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary base cream
Study: 7546114
Drug: Non-thermal pulsed
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-thermal pulsed high-frequency electromagnetic energy treatment for 30 minutes twice daily for 12 weeks
Study: 7546114
Drug: Non-thermal pulsed
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-thermal pulsed high-frequency electromagnetic energy treatment
Study: 766142
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg)
Study: 4042525
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg and 100 mg combined)
Study: 29275880
Drug: Candesartan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan with hydrochlorothiazide (HCTZ; 16 mg/12.5 mg/d)
Study: 16990190
Drug: Hydroxocobalamin (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxocobalamin (2.5, 5, 7.5, or 10 g intravenous doses)
Study: 11020518
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist combined with FSH
Study: 1977703
Drug: Antacids
Normalized name: ANTACIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids
Study: 6985989
Drug: Tolbutamide treatment
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolbutamide treatment
Study: 31564269
Drug: Incentive spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive spirometry (ISM) with steam inhalation and nebulization with beta 2 agonist for 15-20 minutes for 35-45 minutes twice daily for 7 days
Study: 19702079
Drug: SFI 1
Normalized name: Salmeterol Fluticasone Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFI 1 mL/kg after intubation and before blocking the aorta (Group E1)
Study: 19702079
Drug: SFI 1
Normalized name: Salmeterol Fluticasone Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFI 1 mL/kg after opening the aorta (Group E2)
Study: 19702079
Drug: SFI 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFI 0.5 mL/kg twice, before blocking and after opening the aorta (Group E3)
Study: 19702079
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 1 mL/kg after intubation (Group C)
Study: 16551919
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block with 0.25% bupivacaine 15 mL on each side
Study: 12571670
Drug: Exposure-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based intervention (tasting sweet red pepper for 8 daily sessions)
Study: 9331228
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg oral alprazolam
Study: 2441631
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose epidural anesthesia with 2% lidocaine-0.2% tetracaine
Study: 16702981
Drug: Lisinopril (L)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (L)
Study: 28940451
Drug: Vilaprisan 1
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 1 mg/day
Study: 28940451
Drug: Vilaprisan 4
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 4 mg/day
Study: 28940451
Drug: Vilaprisan ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan ≥1 mg/day
Study: 21688876
Drug: Daily estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily estimated blood alcohol concentration (eBAC)
Study: 17962423
Drug: Osmotic-controlled extended-release
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-controlled extended-release methylphenidate (108 mg)
Study: 17962423
Drug: Osmotic-controlled extended-release
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-controlled extended-release methylphenidate (54 mg)
Study: 17962423
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (50 mg)
Study: 12228819
Drug: Atovaquone/proguanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone/proguanil (1 Malarone tablet per day for 20 weeks; n=148)
Study: 7821106
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg isosorbide dinitrate
Study: 27052634
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg three times a day)
Study: 2687557
Drug: Capoten monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capoten monotherapy
Study: 2687557
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with glycosides and saluretics
Study: 3430953
Drug: Furosemide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (mean dose = 172 mg)
Study: 26891756
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily added to aspirin 81 mg/day
Study: 26891756
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to aspirin 81 mg/day
Study: 22434340
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g diluted in 10 ml of lidocaine 1% administered periprostatically and ciprofloxacin orally
Study: 22434340
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml lidocaine 1% administered before TRUS gpb
Study: 2405920
Drug: Serum beta
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum beta 2 microglobulin levels ≥ 6 micrograms/mL
Study: 6986896
Drug: Intranasal flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal flunisolide (300 microgram/day)
Study: 24468920
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy with sudden gains
Study: 22694829
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg q3w x 4 doses) + placebo
Study: 22694829
Drug: gp100 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp100 vaccine + placebo
Study: 17300626
Drug: Once-daily regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimen of artemether-lumefantrine (AL) with 200 ml flavoured milk for 3 days
Study: 17300626
Drug: Conventional twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional twice-daily regimen of artemether-lumefantrine (AL) with 200 ml flavoured milk for 3 days
Study: 17300626
Drug: Six-dose arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six-dose arm (twice-daily regimen)
Study: 17300626
Drug: Three-dose arm
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose arm (once-daily regimen)
Study: 12845653
Drug: Antihistamine users
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine users
Study: 9869600
Drug: Fedotozine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fedotozine (100 mg intravenous infusion)
Study: 2072147
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of etoposide (target WBC nadir of 1,700/microL)